No Detail Found!

Efects of combined sintilimab and chemotherapy on progression-free survival and overall survival in osteosarcoma patients with metastasis

Author(s)
Fan Li Department of Orthopaedics, Affiliated Hospital of Beihua University, 132011 Jilin, P. R. China.
De-bao Zhang Department of Orthopaedics, Affiliated Hospital of Beihua University, 132011 Jilin, P. R. China.
Yue Ma Department of Orthopaedics, Affiliated Hospital of Beihua University, 132011 Jilin, P. R. China.
Yang Song Department of Orthopaedics, Affiliated Hospital of Beihua University, 132011 Jilin, P. R. China.
Xian-liang Duan Department of Orthopaedics, Affiliated Hospital of Beihua University, 132011 Jilin, P. R. China.
Abstract
Objective: To explore the safety and eficacy of metastatic osteosarcoma treatment with combined sintilimab injection and chemotherapy. Methods: We performed a retrospective analysis of 32 patients with metastatic osteosarcoma admitted to the Afiliated Hospital of Beihua University between January 2019 and June 2020. The sample was divided into an observation group, treated with sintilimab injection combined with chemotherapy (n= 16) and a control group, treated with chemotherapy (n = 16). Clinical eficacy and adverse reactions were compared between the two groups. Results: The overall response rates were 68.75% in the observation group and 31.25% in the control group (p < 0.05). The incidences of adverse reactions were 56.25% in the observation group and 81.25% in the control group. This was not a significant diference. In the observation group, the progression-free survival time was 8.13 ± 2.50 months, and the overall survival time was 22.75 ± 4.95 months. These were both significantly longer than the respective 6.44 ± 1.93 months and 19.69 ± 2.68 months in the control group (p < 0.05). Conclusion: The treatment of metastatic osteosarcoma with combined sintilimab injection and chemotherapy was found to prolong progression-free survival and overall survival time without increasing the incidence of adverse reactions.
Publication Details
Page(s) 648-651
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
Safety, Sintilimab, eficacy, Metastatic osteosarcoma
0

Citations

0

Downloads

73

Views